
Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
from FDA,2024.01
During treatment with Selumetinib, in addition to its expected therapeutic effects, this medication may cause some adverse effects. While not all side effects occur, some may requi···【more】
Article source:Lucius LaosRelease date:2026-03-10Recommended:8
Koselugo is suitable for treating children aged 2 years and above with type 1 neurofibromatosis.【more】
Article source:Lucius LaosRelease date:2026-01-05Recommended:16
Koselugo is a class of precision small molecule MEK inhibitors (also regarded as schizogenic activation antagonists), and its core efficacy focuses on targeted therapy for specific···【more】
Article source:Lucius LaosRelease date:2024-08-22Recommended:232
Koselugo is a small molecule MEK inhibitor (figogen activation inhibitor) that is mainly used for the treatment of certain types of tumors, especially in the treatment of neurofibr···【more】
Article source:Lucius LaosRelease date:2024-08-22Recommended:234
Koselugois a small molecule drug inhibitor targeting the MEK signaling pathway, and its core utility is focused on specific neurofibromas and has demonstrated excellent therapeutic···【more】
Article source:Lucius LaosRelease date:2024-08-21Recommended:207

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: